Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($0.60), $0.03 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $8.33 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.